National Studies for Childhood Germ Cell: 1073 Patients. Intermediate Risk with Cisplatin/Etoposide (PE) and no Bleomycin. High Risk Good Responders (HR-GR) with Excellent Results

著录项

• 来源
  《Pediatric blood & cancer 》 |2018年第2期| 共1页
• 作者

  Lopes L. F.; Donato Macedo C. R.; Eiras Martins G.; Brandalise S. R.; Sonaglio V.; Milone Silva M.; de Assis Almeida M. T.; Watusi F.; Albonei Pianovski M.; Melaragno R.; Scridelli C. A.;

  展开▼
• 作者单位

  Children Canc Hosp Barretos Canc Ctr Barretos Brazil;

  Univ Fed Sao Paulo Inst Oncol Pediat GRAACC Pediat Oncol Sao Paulo Brazil;

  Barretos Canc Ctr Children Canc Ctr Barretos Brazil;

  Ctr Infantil Boldrini Pediat Oncol Campinas SP Brazil;

  AC Carmargo Canc Ctr Pediat Oncol Sao Paulo Brazil;

  Ctr Tratamento Fabiana Macedo Moraes GACC Pediat Oncol Sao Jose Dos Campos Brazil;

  Univ Sao Paulo FMUSP Itaci Pediat Oncol Sao Paulo Brazil;

  Hosp Crianca Brasilia Jose de Alencar Pediat Oncol Brasilia DF Brazil;

  Hosp Erasto Gaertner Pediat Oncol Curitiba Parana Brazil;

  Hosp Santa Marcelina Pediat Oncol Sao Paulo Brazil;

  USP Ribeirao Preto Fac Med Pediat Oncol Ribeirao Preto Brazil;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 儿科学 ;
• 关键词